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Abstract
Background: Many herbal medicines are traditionally used as anti-fatigue agents in east Asian countries; however,
there is a dearth of clinical evidence supporting the anti-fatigue effects of such medicines and their mechanisms.
This study is a feasibility trial to assess the clinical efficacy of Gongjin-dan (GJD) and verify its mechanisms by
exploring fatigue outcomes, including endocrine and immunological biomarkers in humans.
Methods/Design: To investigate the anti-fatigue effects of GJD and the mechanism underlying these effects, a
randomised, double-blind, placebo-controlled crossover clinical trial was designed. Participants (24 healthy male
volunteers) will be hospitalised for 4 days (3 nights), during which acute fatigue and stress conditions will be induced
by sleep deprivation, and GJD or a placebo will be administered (twice daily). The primary outcome will be changes in
serum cortisol levels, measured in the morning, as an objective biomarker of sleep deprivation-induced fatigue and
stress. The secondary outcomes will include: the Fatigue Severity Scale; the Brief Fatigue Inventory, and the Leeds
Sleep Evaluation Questionnaire scores; levels of salivary cortisol, epinephrine, norepinephrine, oxidative stress-
related biomarkers, homocysteine, and immunological factors; and heart rate variability. After a washout period of
more than 4 weeks, a second treatment phase will commence in which participants who were previously administered
the placebo will receive the drug and vice versa, following the same treatment regime as in the first phase.
Discussion: This study protocol provides a unique opportunity to enhance our understanding of fatigue and the effects
of GJD on fatigue in terms of endocrine and immunological mechanisms by validating the study design and
determining feasibility. Findings from this trial will help researchers to design a pilot or definitive clinical trial of traditional
herbal medicine for chronic fatigue.
Trial registration: Korean National Clinical Trial Registry CRIS; KCT0001681, registered on 29 October 2015.
Keywords: Fatigue, Traditional herbal medicine, Randomised controlled trial, Protocol
Abbreviations: ALT, Alanine aminotransferase; ANOVA, Analysis of variance; AST, Aspartate aminotransferase;
BFI-K, Brief Fatigue Inventory-Korean version; CAM, Complementary and alternative medicine; CV, Coefficient
variation; ECG, Electrocardiogram; ELISA, Enzyme-linked immunosorbent assay; FAS, Full analysis set; FSS-K,
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the Fatigue Severity Scale-Korean version; GJD, Gongjin-dan; GSH, Glutathione; GSH-Rx, Glutathione reductase;
HF, High frequency; HRV, Heart rate variability; IL, Interleukin; INF-γ, Interferon gamma; ITT, Intention-to-treat;
KMLSEQ, Korean Version of the Modified Leeds Sleep Evaluation Questionnaire; LF, Low frequency;
MDA, Malondialdehyde; MFDS, Ministry of Food and Drug Safety; NK cells, Natural killer cells; NN intervals, Normal-to-
normal intervals; NN50, Number of interval differences of successive NN intervals greater than 50 ms; NO, Nitric oxide;
pNN50, Proportion of NN50 divided by total number of the mean of all normal NN intervals; PP, Per-protocol; PSQI-
K, Pittsburgh Sleep Quality Index-Korean version; RMSSD, Root mean square of successive NN interval differences;
ROS, Reactive oxygen species; RRNN, Mean of normal-to-normal intervals, which is all intervals between adjacent QRS
complexes; SDNN, Standard deviation of NN intervals; SOD, Superoxide dismutase; TAC, Total antioxidant capacity; TNF-
α, Tumour necrosis factor alpha; TP, Total power; VAS, Visual Analogue Scale; VLF, Very low frequency
Background
Fatigue is a subjective symptom of lethargy experienced
during or after performing daily work, or a feeling of a
lack of energy sufficient to affect daily life. The average
worldwide incidence of chronic fatigue is 11.1 % and
most fatigue resolves with rest; however, treatment is
required when fatigue is prolonged and reduces the
quality of life of individuals and their families, or gener-
ally affects society [1, 2]. Among people with chronic fa-
tigue, labor force productivity is known to decrease by
54 % and the cost of lost productivity is estimated to be
$9.1 billion annually in the US. [3].
Fatigue is a multifactorial condition and the patho-
physiological mechanisms of idiopathic chronic fatigue
or chronic fatigue syndrome are unclear. For this reason,
there is no standard treatment for chronic fatigue [4]
and some patients with chronic fatigue, therefore, turn
to complementary and alternative medicine (CAM) for
treatment [5, 6]. In East Asian countries, CAM in the
form of traditional herbal medicine is widely used to treat
fatigue [7, 8]; the traditional herbal drug, Gongjin-dan
(GJD), is generally prescribed by Korean traditional medi-
cine physicians to treat patients with chronic fatigue in
Korean traditional medicine clinics. Although the anti-
fatigue effects of herbal medicines, including GJD [9], deer
antler extract [10], and tao-hong-si-we-tang [11], have
been demonstrated in animal studies, few clinical
studies have focussed on these treatments. To encour-
age evidence-based practices in the traditional medicine
field, well-designed studies must be conducted to evalu-
ate the effects and mechanisms of action of traditional
herbal medicines, including traditional anti-fatigue
medicines.
This study is a feasibility trial to assess the clinical
efficacy of GJD and verify its mechanisms by exploring
fatigue outcomes, including endocrine and immuno-
logical biomarkers. The unique protocol described herein
is designed to minimise confounding factors and other
possible bias, and comprises a randomised, double-blinded,
placebo-controlled crossover clinical trial with hospitalised
subjects. However, the findings from this trial cannot be
generalised to individuals suffering with chronic fatigue
syndrome because sleep-deprived healthy men aged 19–45
years were chosen as the participants of this study to avoid
confounding factors and improve internal validity.
This study design may serve as a guide for researchers
seeking to effectively evaluate the effects and underlying
mechanisms of traditional herbal anti-fatigue medicines
as well as conventional drugs.
Methods
Objective
The aim of this study was to develop a protocol to (1)
evaluate the anti-fatigue effects of GJD in acute fatigue;
(2) verify the mechanisms underlying the observed ef-
fects by assessing changes in stress hormones, oxidative
stress-related biomarkers, homocysteine, and immuno-
logical factors; and (3) clinically assess the effectiveness
and safety of GJD in treating acute fatigue using the
Korean version of the Fatigue Severity Scale (FSS-K),
Brief Fatigue Inventory (BFI-K), and Leeds Sleep Evalu-
ation Questionnaire (KMLSEQ) scores as well as carrying
out daily fatigue and sleep evaluations and assessments of
heart rate variability (HRV) and adverse events.
Design and setting
This randomised, double-blind (both patient and practi-
tioner or assessor), placebo-controlled crossover clinical
trial will be conducted in Republic of Korea.
Recruitment period
Participant recruitment began in September 2015 at the
Daejeon Korean Medicine Hospital of Daejeon University,
and it is expected to be completed in December 2015.
Methods of recruitment
Twenty-four participants will be recruited for this trial,
and participants will be recruited using online and printed
advertisement of the study. Advertisements will be posted
on the online bulletin board of the Daejeon Korean
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Medicine Hospital of Daejeon University, and printed ad-
vertisements will be posted in stores in university towns
and on school bulletin boards. Advertisements will also be
posted on online social networking platforms. The rele-
vant trial information will be conveyed to the potential
participants prior to their first visit to the hospital.
Study plan
Subject information will be collected after oral and written
consent is obtained from each participant at the first visit.
Screening phase After potential participants voluntarily
consent to the study, they will be screened using pre-
determined inclusion/exclusion criteria at the first visit.
The participants will be instructed to sleep for at least
7 h daily for 1 week before admission and to avoid new
medications, alcohol, and caffeine consumption for 2 days
before admission. Participants will be randomly allocated
to one of two groups. The group allocation will be con-
cealed from both the participants and the practitioners.
Treatment and evaluation phase Both the treatment
and placebo-control groups will be hospitalised for
4 days, and after a washout period of over 4 weeks the
participants will be hospitalised again for 4 days. During
hospitalisation, subjects will be administered GJD or pla-
cebo (one pill twice a day 30 min before breakfast and
dinner) for 3 days. Group A participants will be adminis-
tered GJD in phase I, followed by placebo treatment in
phase II (both treatments will be administered twice
daily for 3 days each). Group B participants will be ad-
ministered placebo in phase I, followed by GJD treat-
ment in phase II (same regimen as in group A; Fig. 1).
To assess the effects of GJD treatment, participants will
be allowed to sleep for only 4 h (02:00 to 06:00) on days
2 and 3 to artificially induce fatigue, and will carry out
various activities such as walking, taking lectures, and
watching movies to limit daytime sleep. To control pos-
sible bias, all subjects will be limited to intensive exer-
cise and will consume the same foods during the study
periods.
Blood samples will be collected at 06:30 for analysis of
serum cortisol, stress hormones, oxidative stress-related
biomarkers, homocysteine, and immunological factors.
Saliva samples will be collected at 06:30, 12:00, and 21:00












Control treatment twice daily 
for 3 days
GJD treatment twice daily 
for 3 days
Evaluation Evaluation
Control treatment twice daily 
for 3 days






















Fig. 1 Flowchart describing the study plan
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at 15:00–17:00. Self-reporting of FSS-K, BFI-K, KMLSEQ,
and daily fatigue and sleep status will be carried out via
questionnaires after dinner on days 1, 2, 3, and 4.
After a 4-week washout period, participants will be ad-
mitted to phase II for 4 days, during which they will
undergo the same schedule.
The schedule of events for the trial is outlined in Table 1
and the study participants’ timeline of activities, treatments,
and assessments during hospitalisation is shown in Fig. 2.
Study participants
Inclusion criteria
Participants are eligible for inclusion in the study if they
meet the following criteria:
1. Healthy male volunteers aged 19 to 45 years at the
screening visit
2. Participants must weigh over 45 kg, with a body
mass index of 18.5–30 kg/m2 at the screening visit
3. Participants must not have any congenital defects or
chronic diseases that have been present within the
3 years prior to the screening visit and should have
no pathological or abnormal clinical findings on
physical examination
4. Participants must not have any sleep disorders
and must have Pittsburgh Sleep Quality Index
(Korean version; PSQI-K) scores of 5 points or lower
5. Participant must keep normal nocturnal sleeping
hours (between 21:00 and 09:00) for a week before
Table 1 Schedule of treatments and outcome measurements
aStress hormones; oxidative stress-related biomarkers: serum cortisol, epinephrine, norepinephrine; ROS, NO, MDA, protein carbonyl, GSH, GSH-Rx, SOD,
catalase, TACbImmunological factors: TNF-α, IFN-γ, IL-2, IL-10, IL-12, T cell, B cell, NK cell
● Evaluation at any time; ○ 06:30 (30 min after waking up); ◎ 06:30 (30 min after waking up), 12:00 (before lunch), and 21:00; □ 15:00–17:00 (before dinner);
▣ 07:30–08:30, 12:10–13:00, and 17:30–18:30; ■ 18:30–21:00 (after dinner); ◈ 1 pill twice a day, 30 min before breakfast/dinner
Son et al. Trials  (2016) 17:418 Page 4 of 11
the first administration of the investigational drug
(or placebo)
6. Participants must sleep at least 7 h per night for a
week before the first administration of the
investigational drug (or placebo)
7. Participants must be nonsmokers or ex-smokers
who stopped smoking at least 1 year before the
screening visit
8. Participants must comprehend the purpose and
process of the study as well as the properties of the
investigational drug and must voluntarily sign a
written informed consent approved by the
Institutional Review Board of Daejeon Korean
Medicine Hospital of Daejeon University
Exclusion criteria
Participants who experience, have, or have had one or
more of the following will be excluded:
1. A clinically significant medical history or a
current disease in one of the following areas:
cardiovascular, respiratory, gastrointestinal,
hepatic, metabolic and endocrine, renal and urinary,
reproductive, musculoskeletal, skin and connective
tissue, neurological, psychiatric, or allergic
(other than seasonal allergies that are asymptomatic
at the screening visit) disease
2. A medical history of gastrointestinal diseases
(oesophageal achalasia, oesophageal stricture, or Crohn’s
disease) or operations (other than simple appendectomy
or hernia surgeries) that may affect drug absorption
3. Laboratory test results showing alanine
aminotransferase (ALT) or aspartate
aminotransferase (AST) levels of more than
twice the upper limit of the normal range
4. A history of alcohol or drug abuse within the
12 months before the screening visit
5. History of regular alcohol consumption (>210 g/week)
within the 6 months before the screening visit. (Beer
(5 % v/v): 250 mL = 10 g, soju (20 % v/v): 50 mL = 8 g,
wine (12 % v/v): 125 mL = 12 g)
6. Participation in another clinical study during the
2 months before the screening visit
7. Treatment with drugs with known effects on
drug-metabolising enzymes (e.g. dexamethasone,
phenytoin, carbamazepine, rifabutin, rifampicin,
phenobarbital, ketoconazole, itraconazole,
clarithromycin, atazanavir, indinavir, nelfinavir,
ritonavir, clarithromycin, telithromycin,
voriconazole, etc.) during the 30 days before
the screening visit
8. Whole blood donation during the 2 months before
the screening visit, or specific blood component










































Fig. 2 Timeline of participant activities, treatments, and assessments during each study phase
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9. Seated systolic blood pressure ≥140 mmHg or
diastolic blood pressure ≥90 mmHg at the
screening visit
10. Intake of prescribed or over-the-counter drugs dur-
ing the 7 days before the first administration of the
investigational drug (or placebo)
11. Consumption of alcohol during the 7 days before
the first administration of the investigational drug
(or placebo)
12. Serious, acute, or chronic medical or mental
conditions or abnormal laboratory findings that
may be exacerbated by administration of the
investigational drug or participation in the study,
or that may affect the study outcomes
13. Hypersensitivity to the investigational drug or
any of its components
14. Absence of intention or ability to adhere to the
behavioural rules and requirements as specified in
the present protocol
15. Any person considered unsuitable for participation
in the study by the principal investigator
Intervention
Trial medications will be prepared by Kyoung-Bang
Pharmaceutical Co. Ltd. (Incheon, Republic of Korea)
certified in Good Manufacturing Practices of herbal
medicine extract pills and granules from the Ministry of
Food and Drug Safety (MFDS). Quality control and
quality assurance on the quality and safety testing, the
packaging, and the contents of the treatment interven-
tions including checks for potential contaminants, such
as heavy metals or steroids, will be undertaken by the
manufacturers to ensure treatment drug stability and
quality.
Quality control and quality assurance regarding the
identification of products as well as quality and safety
testing will be conducted by the manufacturer. The raw
herbs will be washed, dried, ground, and mixed with a
pure form of honey (Mel) before being wrapped in gold
foil and formed into pills. The pills will be packaged in
identically shaped containers weighing 3.75 g each. The
GJD and placebo pills will be formulated to a similar
size, shape, taste, and flavour and will be wrapped in
gold foil.
GJD consists of three medicinal herbs (Ginseng radix,
Korean angelica, Corni fructus), two animal-derived
materials (Cornus cervi parvum and Moschus) and Mel.
All constituents of the formulation will comply with
Korean Pharmacopoeia standards [40]. A placebo will
be manufactured by the same pharmaceutical company
and will be comprised of corn starch as the main ingredi-
ent, as well as small amounts of Dioscoreae rhizoma,
Poria sclerotium, Mel, a colouring agent, and a flavour-
ing agent. Each pill will weigh 3.75 g and the amounts
and sources of each component of the formulation are
shown in Table 2. The participants will take GJD or pla-
cebo twice a day 30 min before breakfast and dinner, a
total of six times during hospitalisation.
During the study period, subjects will not be allowed
to receive other fatigue-related treatments such as dietary
supplements or alternatives. A practitioner will check to
ensure that participants have taken the GJD or placebo
immediately after administration and will collect empty
bottles in order to confirm that all doses have been taken.
Outcomes
Detailed outcome measurement time points are pro-
vided in Table 1.
Primary outcome
The primary outcome of this study is the participants’
serum cortisol levels. The effect of GJD on serum corti-
sol will be assessed by observing differences in cortisol
levels before (day 2) and after (day 4) administration
with GJD or placebo dosing after fatigue has been induced
by sleep deprivation in healthy subjects. Considering
circadian rhythms, cortisol will be measured at a spe-
cific time daily. Serum cortisol levels will be mea-
sured on an empty stomach 30 min after waking, and
subjects will not eat foods that might affect cortisol
levels, such as those high in sugar, fat, or protein for
12 h before the first administration of the investiga-
tional drug or placebo [12, 13].
Table 2 Composition of Gongjin-dan
Herbal name Scientific name (local name) Quantity (g/pill) Place of origin
Herbs Corni fructus Cornus officinalis Siebold et Zucc. (山茱萸) 0.9 Korea
Korean angelica Angelica gigas Nakai (當歸) 0.9 Korea
Ginseng radix Panax ginseng C.A. Meyer (人蔘) 0.9 Korea
Animal derives Moschus Moschus moschiferus L. (麝香) 0.15 Russia
Cornus cervi parvum Cervus nippon Temminck (鹿茸) 0.9 Russia
Diluting agents Mel Apis indica Radoszkowski (蜂蜜) Korea
Aurum Gold (金) Korea
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Secondary outcome
Salivary cortisol levels, the secondary outcome of this
study, will be measured once at admission on day 1 at
21:00, and three times daily on days 2–4; for example,
cortisol will be measured within 30 min of waking, at
12:00, and at 21:00. Subjects will not eat within approxi-
mately 1 h or brush their teeth within 10 min before
saliva collection in order to avoid contamination.
Blood samples for analysis of epinephrine, norepineph-
rine, oxidative stress-related biomarkers (reactive oxygen
species (ROS), nitric oxide (NO), malondialdehyde (MDA),
protein carbonyl, glutathione (GSH), GSH reductase
(GSH-Rx), superoxide dismutase (SOD), catalase, and total
antioxidant capacity (TAC)), homocysteine, and immuno-
logical factors (tumour necrosis factor (TNF)-α, interferon
(IFN)-γ, interleukin (IL)-2, IL-10, IL-12, T cells, B cells, and
natural killer (NK) cells) will be collected at the same time
as the serum cortisol samples. Complete blood counts will
be conducted to quantify the populations of T cells, B cells,
and NK cells during phase II, day 2.
A self-reported questionnaire validated for each pur-
pose and modified to a Korean version will be utilised to
measure perceived fatigue. The FSS will be used to
measure overall fatigue status [14], the BFI for variation
in daily fatigue [15, 16], and the LSEQ for variation in
sleep aspects [17]. The nine-item FSS is a self-reporting
questionnaire developed by Krupp et al. [14] and serves
to evaluate fatigue during the past week using state-
ments that the participants must scale from 1 to 7 in
terms of degree of agreement. The BFI is a self-reporting
questionnaire developed by Mendoza et al. [15] to evalu-
ate fatigue in patients with cancer. This nine-item ques-
tionnaire assesses the degree of fatigue at the present
moment and for the past 24 h, as well as the impact of
fatigue on daily life, on a scale of 0 to 10. The LSEQ
consists of 10 items, each of which is measured on the
Visual Analogue Scale (VAS); each item contains oppos-
ite statements at both extremes. The LSEQ involves four
domains related to sleep: ease of initiating sleep (ques-
tions 1, 2, and 3), quality of sleep (questions 4 and 5),
ease of waking (questions 6 and 7), and behaviour after
waking (questions 8, 9, and 10). To complement the re-
sults of the BFI-K and the KMLSEQ, a daily sleep and
fatigue status questionnaire developed by our research
team will also be completed by the participants. This
checks daily sleep and fatigue intuitively on the VAS and
is structured so that participants can spontaneously de-
scribe a variety of their own symptoms.
In the afternoon of days 1–4, HRV testing will be per-
formed to study variations in the autonomic nervous
system responses relevant to fatigue, where HRV is mea-
sured as variations in the beat-to-beat intervals; R is a
point corresponding to the peak of the QRS complex of
the electrocardiogram (ECG) wave and RR is the interval
between successive Rs. For HRV assessments, 5 min of
ECG signalling will be measured and calculated using a
Neo Dinamika system (MR Co. Ltd., Gyeonggi-do, Repub-
lic of Korea). The HRV measurements will be taken after
participants rest for 10 min, and the subjects will be seated
comfortably in a chair in a quiet and bright room at 20–
25 °C for the assessment. The equipment will be con-
nected to the medial side of both wrists and ankles as
well as to the insides of both wrists and the right ankle.
Rhythm parameters of the HRV include pulse rate, vege-
tative balance index, rhythm vegetative factor, regulation
process adequacy index, and tension index. Vegetative
regulation parameters of the HRV include regulation
level and regulation reserves. Statistical analysis of the
HRV includes the RRNN (mean of normal-to-normal
(NN) intervals, which is all intervals between adjacent QRS
complexes); the SDNN (standard deviation of NN inter-
vals); CV (coefficient variation); the RMSSD (the root
mean square of successive NN interval differences); the
NN50 (the number of interval differences of successive
NN intervals greater than 50 ms); and the pNN50 (the
proportion of NN50 divided by total number of the
mean of all normal NN intervals). Spectral analysis in-
cludes HF (high frequency, 0.15–0.4 Hz), LF (low fre-
quency, 0.04–0.15 Hz), VLF (very low frequency, 0.0033
to 0.04 Hz), normalised HF, normalised LF, LF/HF ratio
and TP (total power).
Laboratory analysis
Determining stress hormones
Serum and salivary levels of cortisol as well as serum
levels of norepinephrine and epinephrine will be assessed
using enzyme-linked immunosorbent assay (ELISA) kits
(LDN GmbH & Co., Nordhorn, Germany) according to
the manufacturer’s protocol.
Determining oxidant biomarker levels in serum
Total serum levels of ROS will be determined according
to the method described by Hayashi and colleagues [18].
Serum NO levels will be determined using the Griess
method [19] and serum lipid peroxide levels will be
determined using thiobarbituric acid (TBA) reactive sub-
stances as previously described [20]. The serum levels of
protein carbonyl will be measured using a commercial
ELISA kit (Cell Biolabs Inc., San Diego, CA, USA) and
serum homocysteine levels will be analysed using an
auto-analyser (AU400; Olympus, Tokyo, Japan).
Determining antioxidant biomarker levels in serum
Total antioxidant capacity (TAC) will be determined
using a previously described method [21]. The serum
levels of total glutathione (GSH) and GSH reductase
(GSH-Rx) will be determined using commercial kits
(Abcam, Cambridge, MA, USA) and SOD activity in the
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serum will be determined using an SOD assay kit
(Dojindo Laboratories, Kumamoto, Japan) according to
the manufacturer’s protocol. Serum catalase activities
will be assayed as previously described [22].
Determining immune-related cytokine levels in serum
Serum levels of immune-related cytokines will be mea-
sured using commercial ELISA kits for TNF-α, IFN-γ as
well as IL-2, IL-10, and IL-12 (BD Biosciences, San Jose,
CA, USA). Absorbance will be measured with a spectro-
photometer (Molecular Devices, Sunnyvale, CA, USA).
Flow cytometry and haematological analysis
Lymphocyte subclasses in the peripheral blood will be
analysed using a BD Multitest IMK kit with a FACSCalibur
instrument and Cell Quest Pro software (BD Biosciences,
San Jose, CA, USA). Complete blood counts will be
obtained using a Hemavet analyser (CDC Technologies,
Dayton, OH, USA). T cells (CD3+), B cells (CD19+), and
NK cells (CD3–/CD16+/CD56+) will be quantified as a
percentage of the total number of lymphocytes.
Randomisation and allocation concealment
Randomisation codes will be generated through block
randomisation in a 1:1 code for groups A (phase I: GJD,
phase II: placebo) and B (phase I: placebo, phase II: GJD).
For the generation of a randomisation code, Random
Allocation Software program v2.0.0 (M. Saghaei, MD,
Department of Anaesthesia, Isfahan University of Medical
Sciences, Isfahan, Iran) will be used.
Blinding
A researcher who is not involved in recruitment or as-
sessment will assign the clinical trial subjects identifica-
tion numbers based on the randomisation code in order
to avoid identifying groups. The number will be written
on a piece of paper, put in a sealed envelope so that it is
not visible, and stored in a double-locked cabinet. A re-
searcher who is not involved in the generation of ran-
domisation codes will open the envelopes sequentially
and assign a clinical trial subject to each identification
number. The opened envelope will also be stored separ-
ately in a double-locked cabinet. The clinical trial sub-
jects will be informed that different medicines are given
in phase I and phase II, but will not be told in which
phase the therapeutic medicine is given. The process of
attaching the randomisation code after manufacturing
and packaging of GJD and placebo will be conducted by
a researcher who is not involved in assessments to avoid
breaking the blind. A researcher will provide medication
immediately before each administration time and will
check whether or not the subject takes the medication
to avoid exchanging medicines between subjects during
hospitalisation. To evaluate whether blinding of clinical
trial subjects has been properly conducted, an assess-
ment of blinding will be performed using a self-reported
questionnaire developed by our research team at the end
of the trial, at which point the subjects will be asked in
which phase they perceived to have received the medica-
tion (as opposed to the placebo).
Sample size
No previous clinical trials for serum cortisol levels from
which sample size could be calculated have been re-
ported; however, we consider a sample size of 24 to be a
practical number for detection of clinically important
differences between treatment and control groups. This
number of subjects (12 per group) is the recommended
minimum number per group for pilot studies [23]. We
judged that this pilot study recommendation is applic-
able to feasibility study described here. Based on the
results of this study, pilot trials will be needed in order
to calculate appropriate sample size.
Statistical analysis
An independent statistician who will be blinded to the
randomised allocation for participants will carry out the
statistical analyses. Measured variables including primary
and secondary outcomes will be assessed using the full
analysis set (FAS) based on intention-to-treat (ITT)
principles. The per-protocol (PP) analysis set will be
used for the sensitivity analysis. The baseline charac-
teristics for both randomly allocated sequence groups
are summarised by means and standard deviations for
the continuous variables if satisfying the normal as-
sumption, or median and interquartile range for non-
normal data. Normality will be tested by using the
Shapiro-Wilk test. Frequencies and percentages will
also be presented for categorical variables. The base-
line difference between both sequence groups will be
assessed using an independent two-sample t test or a
Wilcoxon’s rank sum test for continuous variables, and
the chi-squared test or Fisher’s exact test will be used to
verify the randomised allocation for categorical variables.
Changes in serum cortisol levels between the baseline
(day 2) and after treatment with GJD or placebo will be




where C is the change in serum cortisol level, X is the
serum cortisol level, E is the end point, BL is the base-
line, GJD is Gongjin-dan treatment, and PL is placebo.
The primary outcome analysis (Δ = DGJD – DPL) will be
performed in two stages. First, a linear mixed effect
model will be applied to assess the effect of treatment,
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sequence, and period with the random effect for sub-
jects. The carryover effect due to preceding the treat-
ment stage will then be estimated by testing the effect of
sequence in the model. The linear mixed model will be
modified by confounding the sequence effect to the
error term if the carryover effect is not significant.
Otherwise, the model will be rebuilt based on data col-
lected in the first phase of the study. An analysis of
variance (ANOVA) table for the model will be provided
and least square means and their standard errors (95 %
confidence intervals) will be reported for each treatment.
Second, if the structure of data is balanced and the car-
ryover effect is invalid, simple paired two-sample t tests
or Mann Whitney U tests will be performed to evaluate
the effect of GJD. The results will be shown as means
and standard deviations for each treatment group and
mean differences between the two treatments (95 % con-
fidence interval) will be reported.
The analysis of secondary outcomes will be focussed
on changes of measures within each treatment group
from the baseline to the end of study. Again, the linear
mixed effect model will be applied. The level of significance
will be set to 0.05 (two-tailed) and all analyses will be per-
formed with PROC MIXED and PROC GLM in SAS soft-
ware, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Data and safety monitoring
Regular monitoring will be conducted to ensure quality
control of the data according to the planned protocol
and standard operating procedures. Monitors blinded to
the allocation information will evaluate whether the
recruitment procedures are correctly performed and
whether the data are adequately recorded according to
the protocol in the case report forms. If there are neces-
sary changes to the study methods such as changes to
the eligibility criteria, treatment regimens, or follow-up
periods, the investigators will discuss these potential
changes with independent researchers and statisticians.
In the event that severe adverse events and crucial
issues occur, the investigators will determine whether
these issues are acceptable or if the trial should be
amended or ended.
Safety and adverse events
For the safety of study participants, complete blood
counts, liver function tests, and urine analyses will be
performed at the screening phase and the end of phases
I and II, and vital signs will be checked once daily. Con-
tact information will be provided to all participants for
reporting of adverse events at any time. Practitioners
will also check for any expected or unexpected adverse
events every evening of the hospitalisation periods.
Adverse events known to be related to GJD treatment
include gastric discomfort, anorexia, nausea, diarrhoea,
rash, urticaria due to drug-related allergic reaction,
minimal-change disease, and acute focal tubulointersti-
tial nephritis [24]. Any adverse events reported by partici-
pants will be recorded for a causal relationship in the
‘Adverse event record table’. A causal relationship between
the GJD or placebo treatment and adverse events will be
evaluated using a six-grade scale (1 = definitely related,
2 = probably related, 3 = possibly related, 4 = probably
not related, 5 = definitely not related, and 6 = unknown)
and the seriousness of any such events will be scored using
a three-point scale (1 =mild, 2 =moderate, and 3 = severe).
Any adverse events will be reported in accordance with the
regulations of the Institutional Review Board.
Ethics
This study complies with the principles of the Declaration
of Helsinki and Good Clinical Practice guidelines. The
protocol has been reviewed and approved by the Institu-
tional Review Board of the Daejeon Korean Medicine
Hospital of Daejeon University (DJOMC-127-1) and is
registered with the national clinical trial registry Clinical
Research Information Service, which is a primary registry
of the World Health Organisation International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/
Default.aspx; CRIS registration No. KCT0001681). Any
protocol modifications will be approved by the Institu-
tional Review Board of the Daejeon Korean Medicine
Hospital of Daejeon University.
Written informed consent will be obtained from all
study participants prior to enrolment into the study and
participants will be given the option to decline to par-
ticipate or withdraw at any time without disadvantage.
Discussion
Deciding on the appropriate primary outcome of a trial
is one of the challenges of trial design. The primary out-
come in this study protocol is serum cortisol level mea-
sured at 30 min after waking. Cortisol is closely related
to fatigue and blunted cortisol levels are primarily ob-
served in patients with fatigue [25–27]. Although fatigue
is a subjective symptom, cortisol levels were selected as
the primary variable over the questionnaire-derived
results.
Cortisol should be measured at the same time every
day due to circadian rhythm. Cortisol levels may, more-
over, be affected by dietary supplements [28], caffeine
[29], and intensive exercise [30], as well as foods with a
high sugar, fat, or protein content [12, 13]. The cross-
over method and participant hospitalisation were imple-
mented in this study to minimise confounding factors
and other possible bias [31].
To determine perceived symptoms and to compare
these with objective outcomes, the results of self-reported
questionnaires including the FSS-K, BFI-K, KMLSEQ, and
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daily fatigue and sleep evaluation questionnaires will be
evaluated.
Epinephrine, norepinephrine, and HRV are related to
the autonomic nervous system and as such are stimu-
lated as a response to stress in the human body. Most
individuals experiencing fatigue have hyperactive sympa-
thetic nerves and hypoactive parasympathetic nerves
[32, 33], and variations in autonomic nerve activity in
the fatigue state can be observed as changes in serum
concentrations of epinephrine and norepinephrine as
well as in HRV [34].
In comparisons of normal individuals to those experien-
cing fatigue, it has been reported that circulating oxidative
stress increases with fatigue, but that antioxidant levels
decrease [35–37]. Immunity disturbances have been
researched for potential involvement in chronic fatigue
syndrome and analysis of immunological factors are,
therefore, also included in this study [38, 39].
This is a feasibility study and is, thus, not powered to
determine treatment effectiveness. As appropriate sample
size could not be determined due to a lack of similar pre-
vious studies, the minimal sample size considered clinic-
ally significant was defined. The results of this study may,
therefore, affect generalisability in other environments.
Moreover, because fatigue will be artificially induced in
healthy people in this study, the findings would not repre-
sent chronic fatigue, which is more clinically relevant.
Further study with exact sample sizes in patients com-
plaining of chronic fatigue would be necessary and could
be designed based on the results from this study. This
study protocol represents a unique opportunity to en-
hance our understanding of fatigue and the effects GJD on
fatigue in terms of endocrine and immunological mecha-
nisms and may, therefore, serve to improve future treat-
ment strategies for chronic fatigue.
Trial status
Recruitment for this trial opened in September 2015 and
will close in December 2015. At the time of manuscript
submission, the trial was in the recruitment phase.
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